{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:26:35Z","timestamp":1790403995699,"version":"4.1.0"},"reference-count":83,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1038\/ctg.2018.2","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T11:30:29Z","timestamp":1518694229000},"page":"e134","source":"Crossref","is-referenced-by-count":44,"title":["Gut Microbiota-Based Therapies for Irritable Bowel Syndrome"],"prefix":"10.14309","volume":"9","author":[{"given":"Emily K","family":"Stern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren M","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210317","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders.","volume":"150","author":"Lacy","year":"2016","journal-title":"Gastroenterology"},{"key":"R2-2-20210317","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jama.2015.0954","article-title":"Irritable bowel syndrome: a clinical review.","volume":"313","author":"Chey","year":"2015","journal-title":"JAMA"},{"key":"R3-2-20210317","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis.","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R4-2-20210317","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1056\/NEJMra1607547","article-title":"Irritable bowel syndrome.","volume":"376","author":"Ford","year":"2017","journal-title":"N Engl J Med"},{"key":"R5-2-20210317","doi-asserted-by":"crossref","first-page":"151085","DOI":"10.1155\/2012\/151085","article-title":"The gut microbiota and irritable bowel syndrome: friend or foe?","volume":"2012","author":"Ghoshal","year":"2012","journal-title":"Int J Inflam"},{"key":"R6-2-20210317","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1038\/ctg.2016.54","article-title":"Human intestinal barrier function in health and disease.","volume":"7","author":"Konig","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"R7-2-20210317","doi-asserted-by":"crossref","first-page":"G775","DOI":"10.1152\/ajpgi.00155.2012","article-title":"Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome.","volume":"303","author":"Camilleri","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R9-2-20210317","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/gutjnl-2016-312361","article-title":"Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts.","volume":"67","author":"Simren","year":"2018","journal-title":"Gut"},{"key":"R10-2-20210317","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/ajg.2016.223","article-title":"Global cytokine profiles and association with clinical characteristics in patients with irritable bowel syndrome.","volume":"111","author":"Bennet","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"R11-2-20210317","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/ajg.2011.358","article-title":"IBS patients show frequent fluctuations between loosewatery and hardlumpy stools: implications for treatment.","volume":"107","author":"Palsson","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R12-2-20210317","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12876-016-0484-6","article-title":"Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage.","volume":"16","author":"Giamarellos-Bourboulis","year":"2016","journal-title":"BMC Gastroenterol"},{"key":"R13-2-20210317","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5056\/jnm15116","article-title":"Small intestinal bacterial overgrowth in patients with refractory functional gastrointestinal disorders.","volume":"22","author":"Shimura","year":"2016","journal-title":"J Neurogastroenterol Motil"},{"key":"R14-2-20210317","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.3748\/wjg.v20.i10.2482","article-title":"Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype.","volume":"20","author":"Ghoshal","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R15-2-20210317","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s10620-012-2033-7","article-title":"The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome.","volume":"57","author":"Pyleris","year":"2012","journal-title":"Dig Dis Sci"},{"key":"R17-2-20210317","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.cgh.2011.02.030","article-title":"Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective.","volume":"9","author":"Spiegel","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"R18-2-20210317","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1097\/MCG.0000000000000418","article-title":"The intestinal microbiota and irritable bowel syndrome.","volume":"49","author":"Ringel","year":"2015","journal-title":"J Clin Gastroenterol"},{"key":"R19-2-20210317","doi-asserted-by":"crossref","first-page":"9871","DOI":"10.3748\/wjg.v22.i45.9871","article-title":"Gastrointestinal neuromuscular apparatus: an underestimated target of gut microbiota.","volume":"22","author":"Guarino","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R20-2-20210317","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1056\/NEJMra1600266","article-title":"The human intestinal microbiome in health and disease.","volume":"375","author":"Lynch","year":"2016","journal-title":"N Engl J Med"},{"key":"R21-2-20210317","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/gutjnl-2012-302167","article-title":"Intestinal microbiota in functional bowel disorders: a Rome foundation report.","volume":"62","author":"Simren","year":"2013","journal-title":"Gut"},{"key":"R22-2-20210317","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1152\/physrev.00045.2009","article-title":"Gut microbiota in health and disease.","volume":"90","author":"Sekirov","year":"2010","journal-title":"Physiol Rev"},{"key":"R23-2-20210317","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.cell.2016.01.013","article-title":"Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans.","volume":"164","author":"Sender","year":"2016","journal-title":"Cell"},{"key":"R24-2-20210317","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.dld.2017.01.142","article-title":"Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: a systematic review and meta-analysis.","volume":"49","author":"Liu","year":"2017","journal-title":"Dig Liver Dis"},{"key":"R25-2-20210317","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.3748\/wjg.15.2887","article-title":"Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients.","volume":"15","author":"Kerckhoffs","year":"2009","journal-title":"World J Gastroenterol"},{"key":"R26-2-20210317","doi-asserted-by":"crossref","first-page":"G529","DOI":"10.1152\/ajpgi.00207.2012","article-title":"Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome.","volume":"305","author":"Ringel","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R27-2-20210317","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/gut.2007.140210","article-title":"Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity.","volume":"57","author":"Gecse","year":"2008","journal-title":"Gut"},{"key":"R28-2-20210317","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1111\/nmo.12103","article-title":"The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota.","volume":"25","author":"Crouzet","year":"2013","journal-title":"Neurogastroenterol Motil"},{"key":"R31-2-20210317","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2015.02.047","article-title":"Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis.","volume":"161","author":"Yano","year":"2015","journal-title":"Cell"},{"key":"R32-2-20210317","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2982.2012.01891.x","article-title":"Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome.","volume":"24","author":"Carroll","year":"2012","journal-title":"Neurogastroenterol Motil"},{"key":"R33-2-20210317","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2036.2007.03399.x","article-title":"Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome.","volume":"26","author":"Thabane","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R35-2-20210317","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/j.1572-0241.2006.00654.x","article-title":"Postinfectious irritable bowel syndromea meta-analysis.","volume":"101","author":"Halvorson","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R36-2-20210317","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ajg.2012.65","article-title":"Chronic gastrointestinal consequences of acute infectious diarrhea: evolving concepts in epidemiology and pathogenesis.","volume":"107","author":"Verdu","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R37-2-20210317","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2009.12.049","article-title":"Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis.","volume":"138","author":"Villani","year":"2010","journal-title":"Gastroenterology"},{"key":"R38-2-20210317","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1572-0241.2002.05428.x","article-title":"Antibiotics increase functional abdominal symptoms.","volume":"97","author":"Maxwell","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R39-2-20210317","first-page":"17","article-title":"Use of broad-spectrum antibiotics and the development of irritable bowel syndrome.","volume":"111","author":"Villarreal","year":"2012","journal-title":"WMJ"},{"key":"R40-2-20210317","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1007\/s10620-010-1276-4","article-title":"Abnormal breath testing in IBS: a meta-analysis.","volume":"55","author":"Shah","year":"2010","journal-title":"Dig Dis Sci"},{"key":"R41-2-20210317","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1365-2036.2005.02690.x","article-title":"Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome.","volume":"22","author":"Lupascu","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R42-2-20210317","first-page":"412","article-title":"Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study.","volume":"98","author":"Pimentel","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R43-2-20210317","first-page":"139","article-title":"Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.","volume":"52","author":"Majewski","year":"2007","journal-title":"Adv Med Sci"},{"key":"R44-2-20210317","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3109\/00365521.2015.1027261","article-title":"Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome.","volume":"50","author":"Giamarellos-Bourboulis","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"R45-2-20210317","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/ajg.2016.12","article-title":"Food: the main course to wellness and illness in patients with irritable bowel syndrome.","volume":"111","author":"Chey","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"R46-2-20210317","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/gutjnl-2015-311339","article-title":"FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial.","volume":"66","author":"McIntosh","year":"2017","journal-title":"Gut"},{"key":"R47-2-20210317","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ajg.2013.24","article-title":"Food and symptom generation in functional gastrointestinal disorders: physiological aspects.","volume":"108","author":"Farre","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R48-2-20210317","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/ajg.2014.427","article-title":"Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena?","volume":"110","author":"Rajilic-Stojanovic","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R49-2-20210317","doi-asserted-by":"crossref","first-page":"G443","DOI":"10.1152\/ajpgi.00194.2001","article-title":"The proximal colonic motor response to rectal mechanical and chemical stimulation.","volume":"282","author":"Bampton","year":"2002","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R50-2-20210317","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1172\/JCI106644","article-title":"Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man.","volume":"50","author":"Mekhjian","year":"1971","journal-title":"J Clin Invest"},{"key":"R51-2-20210317","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(98)02146-1","article-title":"Abnormal colonic fermentation in irritable bowel syndrome.","volume":"352","author":"King","year":"1998","journal-title":"Lancet"},{"key":"R52-2-20210317","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/apt.13456","article-title":"Review article: insights into colonic protein fermentation, its modulation and potential health implications.","volume":"43","author":"Yao","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R53-2-20210317","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/apt.13469","article-title":"Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders.","volume":"43","author":"Gottlieb","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R54-2-20210317","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/ajg.2009.25","article-title":"The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review.","volume":"104","author":"Brenner","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R55-2-20210317","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1053\/j.gastro.2016.02.028","article-title":"The intestinal microenvironment and functional gastrointestinal disorders.","volume":"105","author":"Barbara","year":"2016","journal-title":"Gastroenterology"},{"key":"R56-2-20210317","first-page":"w14293","article-title":"Gastrointestinal tract: the leading role of mucosal immunity.","volume":"146","author":"Steinert","year":"2016","journal-title":"Swiss Med Wkly"},{"key":"R57-2-20210317","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1113\/jphysiol.2009.176370","article-title":"Effects of probiotics and commensals on intestinal epithelial physiology: implications for nutrient handling.","volume":"587","author":"Resta","year":"2009","journal-title":"J Physiol"},{"key":"R58-2-20210317","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4161\/gmic.22973","article-title":"The intestinal microbiome, probiotics and prebiotics in neurogastroenterology.","volume":"4","author":"Saulnier","year":"2013","journal-title":"Gut Microbes"},{"key":"R59-2-20210317","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1128\/AAC.00161-10","article-title":"Bile acids improve the antimicrobial effect of rifaximin.","volume":"54","author":"Darkoh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R60-2-20210317","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/j.1572-0241.2000.03368.x","article-title":"Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome.","volume":"95","author":"Pimentel","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R61-2-20210317","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1007\/s10620-014-3157-8","article-title":"Antibiotic treatment of constipation-predominant irritable bowel syndrome.","volume":"59","author":"Pimentel","year":"2014","journal-title":"Dig Dis Sci"},{"key":"R62-2-20210317","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.gastro.2013.10.026","article-title":"Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats.","volume":"146","author":"Xu","year":"2014","journal-title":"Gastroenterology"},{"key":"R63-2-20210317","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000068362","article-title":"Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis.","volume":"66","author":"Fiorucci","year":"2002","journal-title":"Digestion"},{"key":"R64-2-20210317","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1128\/AAC.44.8.2205-2206.2000","article-title":"In vitro activity and fecal concentration of rifaximin after oral administration.","volume":"44","author":"Jiang","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R65-2-20210317","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/CEG.S62823","article-title":"Serum-derived bovine immunoglobulinprotein isolate: postulated mechanism of action for management of enteropathy.","volume":"7","author":"Petschow","year":"2014","journal-title":"Clin Exp Gastroenterol"},{"key":"R67-2-20210317","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/ajg.2016.434","article-title":"A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D.","volume":"111","author":"Eswaran","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"R68-2-20210317","doi-asserted-by":"crossref","first-page":"7186","DOI":"10.3748\/wjg.v22.i32.7186","article-title":"Modulation of microbiota as treatment for intestinal inflammatory disorders: an uptodate.","volume":"22","author":"Gallo","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R70-2-20210317","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation.","volume":"364","author":"Pimentel","year":"2011","journal-title":"N Engl J Med"},{"key":"R71-2-20210317","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/j.gastro.2016.08.003","article-title":"Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome.","volume":"151","author":"Lembo","year":"2016","journal-title":"Gastroenterology"},{"key":"R72-2-20210317","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s10620-017-4598-7","article-title":"Repeat rifaximin for irritable bowel syndrome: no clinically significant changes in stool microbial antibiotic sensitivity.","volume":"62","author":"Pimentel","year":"2017","journal-title":"Dig Dis Sci"},{"key":"R73-2-20210317","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/apt.12735","article-title":"Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.","volume":"39","author":"Schoenfeld","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R74-2-20210317","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/apt.12087","article-title":"Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.","volume":"36","author":"Meyrat","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R75-2-20210317","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/MCG.0b013e3181c64c90","article-title":"A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test.","volume":"44","author":"Low","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"R76-2-20210317","doi-asserted-by":"crossref","first-page":"S496","DOI":"10.1016\/S0016-5085(16)31709-7","article-title":"Su1210 SYN-010, a proprietary modified-release formulation of lovastatin lactone, lowered breath methane and improved stool frequency in patients with IBS-C: results of a multi-center randomized double-blind placebo-controlled phase 2a trial.","volume":"150","author":"Gottlieb","year":"2016","journal-title":"Gastroenterology"},{"key":"R78-2-20210317","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/1756283X15593693","article-title":"Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin.","volume":"8","author":"Shafran","year":"2015","journal-title":"Therap Adv Gastroenterol"},{"key":"R79-2-20210317","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3748\/wjg.v21.i11.3361","article-title":"New therapeutic option for irritable bowel syndrome: serum-derived bovine immunoglobulin.","volume":"21","author":"Good","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R80-2-20210317","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4137\/CGast.S13200","article-title":"Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome.","volume":"6","author":"Wilson","year":"2013","journal-title":"Clin Med Insights Gastroenterol"},{"key":"R81-2-20210317","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2036.2008.03911.x","article-title":"Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome.","volume":"29","author":"Silk","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R82-2-20210317","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1017\/S000711450779894X","article-title":"The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders.","volume":"99","author":"Paineau","year":"2008","journal-title":"Br J Nutr"},{"key":"R83-2-20210317","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/ajg.2014.202","article-title":"Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis.","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R84-2-20210317","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1572-0241.2006.00734.x","article-title":"Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.","volume":"101","author":"Whorwell","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R85-2-20210317","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2036.2007.03362.x","article-title":"Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial.","volume":"26","author":"Guyonnet","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R86-2-20210317","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/ajg.2014.187","article-title":"American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation.","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R87-2-20210317","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.clinthera.2005.06.005","article-title":"Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study.","volume":"27","author":"Bittner","year":"2005","journal-title":"Clin Ther"},{"key":"R88-2-20210317","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00394-015-0922-1","article-title":"Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis.","volume":"55","author":"Marsh","year":"2016","journal-title":"Eur J Nutr"},{"key":"R89-2-20210317","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1053\/j.gastro.2015.07.054","article-title":"Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial.","volume":"149","author":"Bohn","year":"2015","journal-title":"Gastroenterology"},{"key":"R90-2-20210317","first-page":"36","article-title":"Controversies and recent developments of the low-FODMAP diet.","volume":"13","author":"Hill","year":"2017","journal-title":"Gastroenterol Hepatol"},{"key":"R91-2-20210317","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/gutjnl-2014-307264","article-title":"Diets that differ in their FODMAP content alter the colonic luminal microenvironment.","volume":"64","author":"Halmos","year":"2015","journal-title":"Gut"}],"container-title":["Clinical and Translational Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01720094-201802000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:21:33Z","timestamp":1786548093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01720094-201802000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1038\/ctg.2018.2","relation":{},"ISSN":["2155-384X"],"issn-type":[{"value":"2155-384X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}